AU2020403266A1 - Methods for treating Parkinson's disease - Google Patents

Methods for treating Parkinson's disease Download PDF

Info

Publication number
AU2020403266A1
AU2020403266A1 AU2020403266A AU2020403266A AU2020403266A1 AU 2020403266 A1 AU2020403266 A1 AU 2020403266A1 AU 2020403266 A AU2020403266 A AU 2020403266A AU 2020403266 A AU2020403266 A AU 2020403266A AU 2020403266 A1 AU2020403266 A1 AU 2020403266A1
Authority
AU
Australia
Prior art keywords
gad
subject
vectors
time
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020403266A
Other languages
English (en)
Inventor
Matthew During
Alexandria FORBES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiragtx Neuro I LLC
Original Assignee
Meiragtx Neuro I LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiragtx Neuro I LLC filed Critical Meiragtx Neuro I LLC
Publication of AU2020403266A1 publication Critical patent/AU2020403266A1/en
Assigned to MeiraGTx Neuro I, LLC reassignment MeiraGTx Neuro I, LLC Request for Assignment Assignors: MEIRAGTX UK II LIMITED
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020403266A 2019-12-12 2020-12-14 Methods for treating Parkinson's disease Pending AU2020403266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947418P 2019-12-12 2019-12-12
US62/947,418 2019-12-12
PCT/US2020/064928 WO2021119615A1 (en) 2019-12-12 2020-12-14 Methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
AU2020403266A1 true AU2020403266A1 (en) 2022-08-04

Family

ID=76330812

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020403266A Pending AU2020403266A1 (en) 2019-12-12 2020-12-14 Methods for treating Parkinson's disease

Country Status (10)

Country Link
US (1) US20230050187A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072568A4 (cg-RX-API-DMAC7.html)
JP (2) JP7758671B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114028A (cg-RX-API-DMAC7.html)
AU (1) AU2020403266A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161322A1 (cg-RX-API-DMAC7.html)
IL (1) IL293776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007193A (cg-RX-API-DMAC7.html)
WO (1) WO2021119615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085129A1 (en) * 2024-10-15 2026-04-23 MeiraGTx Neuro I, LLC High-dose gad gene therapy for treating parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US20030087264A1 (en) * 2001-05-22 2003-05-08 Kaplitt Michael G. Transcriptional regulation of target genes
EP1893754A4 (en) * 2005-05-31 2009-01-21 Neurologix Inc NEW GLUTAMIC ACID DECARBOXYLASE (GAD) CHIMESES AND USE PROCESSES
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون

Also Published As

Publication number Publication date
KR20220114028A (ko) 2022-08-17
US20230050187A1 (en) 2023-02-16
EP4072568A1 (en) 2022-10-19
EP4072568A4 (en) 2024-02-07
JP7758671B2 (ja) 2025-10-22
MX2022007193A (es) 2022-09-19
BR112022011584A2 (pt) 2022-12-13
JP2023506007A (ja) 2023-02-14
IL293776B1 (en) 2026-07-01
WO2021119615A1 (en) 2021-06-17
CA3161322A1 (en) 2021-06-17
JP2025188191A (ja) 2025-12-25
IL293776A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US7645446B2 (en) Glutamic acid decarboxylase (GAD) based delivery system
US7588757B2 (en) Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US7955595B2 (en) Glutamic acid decarboxylase (GAD) based delivery system
TW201919713A (zh) 用於帕金森氏症之aadc多核苷酸
AU2001268080A1 (en) Glutamic acid decarboxylase (gad) based delivery systems
JP2025188191A (ja) パーキンソン病を治療するための方法
US9333243B2 (en) Gene delivery vehicles in the treatment of neurodegenerative diseases
Higuchi et al. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA
CN117122688B (zh) 作用于前脑兴奋性神经元的prrt2及其上调剂的应用
EA051580B1 (ru) Способы лечения болезни паркинсона
CN115135347A (zh) 治疗帕金森病的方法
Kells et al. GDNF Gene Therapy for Parkinson’s Disease
WO2026085129A1 (en) High-dose gad gene therapy for treating parkinson's disease
Elder AADC gene therapy for Parkinson’s disease
TW202111126A (zh) 用於治療聖菲利柏氏病及其他病症之組合物及方法
US20250360226A1 (en) Oxr1 gene therapy
US20220364118A1 (en) Targeting deltafosb for treatment of dyskinesia
Simonato et al. Gene Therapy for Neurological Diseases
TW202608488A (zh) 基因治療
Sahu et al. Gene therapy under clinical trials for neurodegenerative diseases
Bankiewicz et al. GDNF and AADC Gene Therapy for Parkinson’s Disease
CA3255025A1 (en) METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF PARKINSON'S DISEASE
CN118725046A (zh) 具有经修饰的腺相关病毒(aav)衣壳多肽的重组aav

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MEIRAGTX NEURO I, LLC

Free format text: FORMER APPLICANT(S): MEIRAGTX UK II LIMITED